H
Hugues de Lavallade
Researcher at University of Cambridge
Publications - 67
Citations - 3014
Hugues de Lavallade is an academic researcher from University of Cambridge. The author has contributed to research in topics: Transplantation & Internal medicine. The author has an hindex of 17, co-authored 57 publications receiving 2363 citations. Previous affiliations of Hugues de Lavallade include King's College London & Guy's and St Thomas' NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy-Is it prognostic?-a single-center retrospective study.
Vipul S Sheth,Vipul S Sheth,Victoria T Potter,Hugues de Lavallade,Shreyans Gandhi,Austin G. Kulasekararaj,Pramila Krishnamurthy,Varun Mehra,Francesco Dazzi,Ghulam J. Mufti,Antonio Pagliuca,Donal Mclornan,Donal Mclornan,K Raj,K Raj +14 more
TL;DR: In this paper, pre-emptive DLI (pDLI) is an effective strategy in lowering the risk of relapse without significantly increasing the risk for graft-versus-host disease (GVHD) in the case of T cell lineage mixed chimerism (MC) post allogeneic transplant in hematological malignancies.
Journal ArticleDOI
Uniparental disomy (UPD) of a novel bisphosphoglycerate mutase (BPGM) mutation leading to erythrocytosis.
Ioanna Lazana,Azim M Mohamedali,Frances Smith,Hugues de Lavallade,Hugues de Lavallade,Donal P. McLornan,Kavita Raj +6 more
TL;DR: The distribution of age, IPI score, COO, tumour histology and treatment regimen is shown for each of the subgroups classified by LymphGen or the modified HMRN criteria.
Journal ArticleDOI
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
P. Harrington,Katie J. Doores,Jamie G. Saunders,Marc de Lord,Chandan Saha,Thomas Lechmere,Hataf Khan,Ho Pui Jeff Lam,Amy Reilly,Claire Woodley,S. Asirvatham,Richard Dillon,Natalia Curto-Garcia,Jennifer O’ Sullivan,Shahram Kordasti,Kavita Raj,Michael H. Malim,Deepti Radia,Donal P. McLornan,Claire N. Harrison,Hugues de Lavallade +20 more
TL;DR: The humoral and T cell responses induced by sequential doses of vaccination against SARS-Cov-2 in patients with chronic myeloproliferative neoplasms are reported as well as the early protective effect on infection in these patients.
Journal ArticleDOI
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years.
Vipul Sharad Sheth,Victoria Potter,Shreyans Gandhi,Shreyans Gandhi,Austin G. Kulasekararaj,Hugues de Lavallade,Hugues de Lavallade,Petra Muus,Antonio Pagliuca,Antonio Pagliuca,Carmel Rice,Varun Mehra,Francesco Grimaldi,Francesco Grimaldi,Shafqat Inam,Linda Barber,Ghulam J. Mufti,Ghulam J. Mufti,Judith C. W. Marsh,Judith C. W. Marsh +19 more
TL;DR: Effect of comorbidities rather than age alone may be a more important determinant of suitability for FCC HSCT in older patients.
Journal ArticleDOI
A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).
Muna Ghazzawi,Varun Mehra,Marcin Knut,Loretta Brown,William J. Tapper,Andrew Chase,Hugues de Lavallade,Nicholas C.P. Cross +7 more
TL;DR: Disruption of PDGFRB was confirmed in both the original and follow-up samples and Retrospective analysis of the original diagnostic sample revealed the same abnormality, which had originally been misinterpreted due to poor-quality metaphases.